These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22915993)

  • 1. A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patients.
    Choe S; Kim G; Lim HS; Cho SH; Ghim JL; Jung JA; Kim UJ; Noh G; Bae KS; Lee D
    Korean J Physiol Pharmacol; 2012 Aug; 16(4):273-80. PubMed ID: 22915993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.
    Cho SH; Lee JH; Lim HS; Lee KH; Kim DY; Choe S; Bae KS; Lee JH
    Korean J Physiol Pharmacol; 2016 May; 20(3):245-51. PubMed ID: 27162478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
    Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
    J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.
    Diestelhorst C; Boos J; McCune JS; Hempel G
    Eur J Clin Pharmacol; 2014 Jul; 70(7):839-47. PubMed ID: 24810613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
    Takama H; Tanaka H; Nakashima D; Ueda R; Takaue Y
    Bone Marrow Transplant; 2006 Feb; 37(4):345-51. PubMed ID: 16400337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
    Lawson R; Staatz CE; Fraser CJ; Ramachandran S; Teague L; Mitchell R; O'Brien T; Hennig S
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1002-1017. PubMed ID: 35611997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
    Takahashi T; Illamola SM; Jennissen CA; Long SE; Lund TC; Orchard PJ; Gupta AO; Long-Boyle JR
    Transplant Cell Ther; 2022 Feb; 28(2):104.e1-104.e7. PubMed ID: 34883294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Clemmons AB; Evans S; DeRemer DL; Awan FT
    J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.
    Takahashi T; Jaber MM; Brown SJ; Al-Kofahi M
    Clin Pharmacokinet; 2023 Jul; 62(7):955-968. PubMed ID: 37415003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
    Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
    Ryu SG; Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Hur EH; Lee SH; Bae KS; Noh GJ; Lee MS; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1095-105. PubMed ID: 17697972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children.
    Marsit H; Philippe M; Neely M; Rushing T; Bertrand Y; Ducher M; Leclerc V; Guitton J; Bleyzac N; Goutelle S
    Clin Pharmacokinet; 2020 Aug; 59(8):1049-1061. PubMed ID: 32157629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.